{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:19:57Z","timestamp":1787732397669,"version":"build-2784847793"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007225","name":"Socialist Republic of Vietnam Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Journal"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bj.2026.101014","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:15:14Z","timestamp":1783379714000},"page":"101014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of HBsAg levels and HBV relapse patterns with HBsAg seroclearance following entecavir or tenofovir cessation"],"prefix":"10.1016","author":[{"given":"Yuan-Hung","family":"Kuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hao","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Houng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bj.2026.101014_bib1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.bj.2026.101014_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hep.24361","article-title":"Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.bj.2026.101014_bib3","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1007\/s12072-013-9440-5","article-title":"A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-na\u00efve and -experienced adult Taiwanese chronic hepatitis B patients","volume":"7","author":"Chen","year":"2013","journal-title":"Hepatol Int"},{"key":"10.1016\/j.bj.2026.101014_bib4","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jhep.2012.04.037","article-title":"Long-term continuous entecavir therapy in nucleos(t)ide-na\u00efve chronic hepatitis B patients","volume":"5","author":"Ono","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.bj.2026.101014_bib5","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.26549","article-title":"Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients","volume":"58","author":"Jeng","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.bj.2026.101014_bib6","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jhep.2014.04.029","article-title":"The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment","volume":"61","author":"Chen","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.bj.2026.101014_bib7","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.cgh.2015.06.002","article-title":"Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection","volume":"13","author":"Chen","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bj.2026.101014_bib8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.bj.2026.101014_bib9","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/infdis\/jiy697","article-title":"The Incidence of Hepatitis B Surface Antigen Loss Between Hepatitis B E Antigen-Negative Noncirrhotic Patients Who Discontinued or Continued Entecavir Therapy","volume":"219","author":"Chen","year":"2019","journal-title":"J Infect Dis."},{"key":"10.1016\/j.bj.2026.101014_bib10","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jhep.2022.12.018","article-title":"A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B","volume":"78","author":"van B\u00f6mmel","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.bj.2026.101014_bib11","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/apt.17602","article-title":"Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B","volume":"58","author":"Chen","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bj.2026.101014_bib12","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study","volume":"67","author":"Berg","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.bj.2026.101014_bib13","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.cmi.2017.12.013","article-title":"Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients","volume":"24","author":"Chen","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.bj.2026.101014_bib14","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.bj.2026.101014_bib15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.bj.2026.101014_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/00365521.2018.12027892","article-title":"Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan","volume":"38","author":"Lee","year":"2003","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.bj.2026.101014_bib17","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/jac\/dkac409","article-title":"Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation","volume":"78","author":"Tseng","year":"2023","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.bj.2026.101014_bib18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/apt.70332","article-title":"Long-Term Follow-Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss","volume":"63","author":"Hume","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bj.2026.101014_bib19","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/infdis\/jiy097","article-title":"Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss","volume":"217","author":"Zimmer","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bj.2026.101014_bib20","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2018.05.004","article-title":"Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B","volume":"69","author":"Rinker","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.bj.2026.101014_bib21","first-page":"592","article-title":"Differential response of HBV envelope-specific CD4 + T cells is related to HBsAg loss after stopping nucleos(t)ide analogue therapy","volume":"78","author":"Li","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.bj.2026.101014_bib22","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jhep.2024.08.015","article-title":"Predictors of hepatic flares after nucleos(t)ide analogue cessation - Results of a global cohort study (RETRACT-B study)","volume":"82","author":"Dongelmans","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.bj.2026.101014_bib23","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/apt.18515","article-title":"Association Between Elevation of Serum Alanine Aminotransferase and HBsAg Seroclearance After Nucleos(t)ide Analog Withdrawal","volume":"61","author":"Tsai","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bj.2026.101014_bib24","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.jhep.2014.08.033","article-title":"Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management","volume":"61","author":"Chang","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.bj.2026.101014_bib25","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S2468-1253(19)30344-9","article-title":"Serum Alanine Aminotransferase Flares in Chronic Hepatitis B Infection: The Good and the Bad","volume":"5","author":"Ghany","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.bj.2026.101014_bib26","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/17474124.2022.2156338","article-title":"Hepatitis B flare: the good, the bad and the ugly","volume":"16","author":"Liaw","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.bj.2026.101014_bib27","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.14309\/ajg.0000000000002203","article-title":"Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)","volume":"118","author":"Hirode","year":"2023","journal-title":"Am J Gastroenterol"}],"container-title":["Biomedical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417026000703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417026000703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:33:44Z","timestamp":1787729624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2319417026000703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":27,"alternative-id":["S2319417026000703"],"URL":"https:\/\/doi.org\/10.1016\/j.bj.2026.101014","relation":{},"ISSN":["2319-4170"],"issn-type":[{"value":"2319-4170","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of HBsAg levels and HBV relapse patterns with HBsAg seroclearance following entecavir or tenofovir cessation","name":"articletitle","label":"Article Title"},{"value":"Biomedical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bj.2026.101014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chang Gung University.","name":"copyright","label":"Copyright"}],"article-number":"101014"}}